GoAI
Get started
Pulse Biosciences, Inc. logo

Pulse Biosciences, Inc.

PLSE

NASDAQHealthcareMedical - Instruments & Supplies

Open in GoAI

Regular session

$49.75

−$0.67 · -1.33%

Aug 24, 11:52 AM ETData delayed

PLSE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

13

Overpriced

Momentum

62

Gaining

Sentiment

63

Bullish

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Paul Arthur LaViolette
Listed since
May 18, 2016
Employees
116

Market position

Day range

Current $49.75

52-week range

Current $49.75

Open
$50.01
Previous close
$50.42
Volume
128.24K
0.35× average
Average volume
366.55K
Average daily volume
Market cap
3.44B USD
Beta
1.58
Market reference 1
50-day average
$33.0137
+50.70% above average
200-day average
$22.3116
+122.98% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
852.13M USD
P/E (TTM)
-42.52×
P/B (TTM)
34.6×
P/S (TTM)
2,905.64×
EV / EBITDA
-11.88×
Earnings yield
-7.87%
Free cash flow yield
-5.88%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-21.60%
Operating margin
-7007.76%
Net margin
-6755.78%
Return on equity
-90.24%
Return on assets
-75.72%
Return on invested capital
-85.72%

Financial health

Debt / equity
0.07×
Current ratio
10.53×
Altman Z-score
122.89
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2156%-6622%-15399%-24177%Gross margin, FY2021: -38.79%Gross margin, FY2022: -1606.29%Gross margin, FY2025: -360.00%Operating margin, FY2021: -4443.86%Operating margin, FY2022: -8293.86%Operating margin, FY2025: -21982.57%Net margin, FY2021: -4489.42%Net margin, FY2022: -8357.86%Net margin, FY2025: -20794.57%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -38.79%. Gross margin FY2022 -1606.29%. Gross margin FY2025 -360.00%. Operating margin FY2021 -4443.86%. Operating margin FY2022 -8293.86%. Operating margin FY2025 -21982.57%. Net margin FY2021 -4489.42%. Net margin FY2022 -8357.86%. Net margin FY2025 -20794.57%.

Income trends

Revenue

350K USD-50.00%

Operating income

−76.94M USD-36.76%

Net income

−72.78M USD-35.82%
Income trends across reported periods9.25M USD−22.09M USD−53.43M USD−84.77M USDRevenue, FY2021: 1.42M USDRevenue, FY2022: 700K USDRevenue, FY2025: 350K USDOperating income, FY2021: −63.01M USDOperating income, FY2022: −58.06M USDOperating income, FY2023: −43.57M USDOperating income, FY2024: −56.26M USDOperating income, FY2025: −76.94M USDNet income, FY2021: −63.66M USDNet income, FY2022: −58.51M USDNet income, FY2023: −42.21M USDNet income, FY2024: −53.59M USDNet income, FY2025: −72.78M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.42M USD. Revenue FY2022 700K USD. Revenue FY2025 350K USD. Operating income FY2021 −63.01M USD. Operating income FY2022 −58.06M USD. Operating income FY2023 −43.57M USD. Operating income FY2024 −56.26M USD. Operating income FY2025 −76.94M USD. Net income FY2021 −63.66M USD. Net income FY2022 −58.51M USD. Net income FY2023 −42.21M USD. Net income FY2024 −53.59M USD. Net income FY2025 −72.78M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue350K USD——700K USD1.42M USD
Cost of goods sold1.61M USD—1.21M USD11.94M USD1.97M USD
Gross profit−1.26M USD—−1.21M USD−11.24M USD−550K USD
Research and development44.72M USD32.34M USD27.8M USD20.84M USD28.64M USD
Selling, general, and administrative32.03M USD23.92M USD15.78M USD25.97M USD33.82M USD
Operating expenses75.68M USD56.26M USD42.37M USD46.81M USD62.46M USD
Interest income4.21M USD2.67M USD2.46M USD——
Interest expense——1.1M USD448K USD646K USD
Depreciation and amortization1.07M USD1.18M USD1.21M USD1.36M USD1.15M USD
Operating income−76.94M USD−56.26M USD−43.57M USD−58.06M USD−63.01M USD
Net income−72.78M USD−53.59M USD−42.21M USD−58.51M USD−63.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
80%
8 beats, 2 misses, 0 met estimates
Average EPS surprise
+15.85%
10 comparable reports
Latest EPS result
-0.36
Estimate -0.31 · Miss by 16.13%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.14-0.23-0.31-0.4Q1 '25BeatQ2 '25No estimateQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.17, estimate -0.24, surprise +29.17%, Beat. Q2 2025, reported May 8, 2025: actual -0.17, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual -0.28, estimate -0.26, surprise -7.69%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.29, estimate -0.31, surprise +6.45%, Beat. Q1 2026, reported Feb 19, 2026: actual -0.26, estimate -0.265, surprise +1.89%, Beat. Q2 2026, reported May 4, 2026: actual -0.27, estimate -0.32, surprise +15.62%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.36, estimate -0.31, surprise -16.13%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.35, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.87M1.27M672.84K73.1KQ1 '24No estimateQ3 '25EstimateQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2024, reported Mar 28, 2024: actual 1.74M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual —, estimate 500K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 5, 2025: actual 86K USD, estimate 500K USD, surprise -82.80%, Miss. Q1 2026, reported Feb 19, 2026: actual 264K USD, estimate 150K USD, surprise +76.00%, Beat. Q2 2026, reported May 4, 2026: actual 400K USD, estimate 250K USD, surprise +60.00%, Beat. Q3 2026, reported Aug 6, 2026: actual 434K USD, estimate 500K USD, surprise -13.20%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 625K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$45.25

9.05% downside
Past 12 months12-month forecastHigh $58.00Average $45.25Low $35.00

Rating distribution

5 ratings
Strong buy00%
Buy360%
Hold240%
Sell00%
Strong sell00%

Recent analyst actions

1 institution
Canaccord GenuitymaintainBuy

PLSE news

defenseworld.net

Bank of America Corp DE Grows Stake in Pulse Biosciences, Inc $PLSE

Bank of America Corp DE raised its holdings in shares of Pulse Biosciences, Inc (NASDAQ: PLSE) by 8.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange…

Read source
defenseworld.net

Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Here’s Why

Pulse Biosciences, Inc (NASDAQ: PLSE - Get Free Report) shares reached a new 52-week high during trading on Wednesday. The stock traded as high as $48.10 and last traded at $46.00, with a volume of 525728 shares trading…

Read source
businesswire.com

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the…

Read source
marketbeat.com

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman…

Read source
seekingalpha.com

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Pulse Biosciences Q2 Earnings Call Highlights

Pulse Biosciences NASDAQ: PLSE reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation…

Read source

PLSE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding PLSE

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
24.05M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.62-0.45%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
19.48M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.55-0.18%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
8.78M
Weight
0.06%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$384.51-0.74%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
7.6M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.88-0.67%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
4.54M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.505-0.95%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.66M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.72-0.44%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
3.21M
Weight
0.21%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$197.26-0.45%
State Street SPDR S&P Health Care Equipment ETF logoState Street SPDR S&P Health Care Equipment ETFXHE
Market value
2.76M
Weight
1.57%
AUM
176.38M USD
Expense ratio
0.35%
Price / 1D
$96.195-0.50%

Continue in GoAI

Research PLSE

research.disclaimer